KCAS

Proveen Dass, Ph.D., has been appointed associate director of KCAS, Inc. He joins Masood Khan, Ph.D., senior director of immunoanalytical science and technology, and his ligand binding assay (LBA) team.

Dr. Dass will use his industry experience to assist Dr. Khan with the development of GLP-compliant and non-GLP assays for the large molecule bioanalytical studies, including PK/TK analysis, immunogenicity evaluation and biomarker quantification. KCAS uses immunoanalytical technologies to support large molecule bioanalysis for preclinical and clinical studies (Phase I-IV), as well as bioanalysis for biomarker screening pilot projects.

“We are very fortunate to have both Dr. Khan and Dr. Dass at KCAS,” said president and scientific director of KCAS, Dari Dadgar, Ph.D. “Their combined knowledge and skill in working with large molecules, specifically LBA services, has positively impacted our capabilities and we look forward to propelled growth and expansion in the future.”